Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
15.92
-0.16 (-1.00%)
At close: Apr 27, 2026, 4:00 PM EDT
16.23
+0.31 (1.95%)
After-hours: Apr 27, 2026, 7:35 PM EDT
← View all transcripts

AGM 2023

Jun 15, 2023

Operator

Hello, welcome to the Annual Meeting of Stockholder of Corvus Pharmaceuticals, Inc. Please note that today's meeting is being recorded. During the meeting, we'll have a question and answer session. You can submit questions or comments at any time by clicking on the message icon. It is now my pleasure to turn today's meeting over to Leiv Lea, Corvus CFO. Mr. Lea, the floor is yours.

Leiv Lea
CFO, Corvus Pharmaceuticals, Inc

Thank you, operator. Good afternoon, ladies and gentlemen. Will the meeting please come to order? I would like to welcome all of you to the virtual annual meeting of stockholders of Corvus Pharmaceuticals Inc. I am Leiv Lea, Corvus's CFO, and I will be presiding at this meeting. Also present today are members of our board of directors. Philip Stoop of Latham & Watkins will act as Secretary of the meeting. I've been appointed to act as Inspector of Elections. Usman Kaba of PricewaterhouseCoopers, Corvus's independent registered accounting firm, is also virtually present at the meeting. Registered stockholders can submit questions for the auditors and questions related to the matters being acted upon at this meeting through the virtual meeting portal. The Secretary has delivered an affidavit of mailing, establishing that notice of this meeting was duly given.

A copy of the notice of the meeting and affidavit of mailing will be incorporated into the minutes of the meeting. Only stockholders of record at the close of business on April 18th, 2023, are entitled to vote at this meeting. Our first order of business is to determine whether the shares represented at the meeting, either in person or by proxy, are sufficient to constitute a quorum for the purposes of transacting business. The certified stockholders list shows that holders of 46,568,511 shares of common stock of the company are entitled to vote at this meeting. There are represented in person or by proxy, 36,151,036 shares of common stock, or approximately 77.63% of all the shares entitled to vote at this meeting. Therefore, we have a quorum.

Because holders of the majority of the shares entitled to vote at this meeting are present online or by proxy, I declare this meeting to be duly convened for the purposes of transacting such business as may properly come before it. Please note that the polls are still open for shareholders to vote. For shareholders who have not yet cast their vote via proxy or the virtual meeting portal, you will need to complete that process in the virtual meeting portal prior to the polls closing in order for your vote to be counted. The polls will be closing in just a few minutes. The next order of business is a description of the matters to be voted on at today's meeting. Please note that the polls will be closing once I have finished discussing these proposals, so any final votes should be cast now.

The first proposal to be voted upon is the election of 2 Class I directors to serve until the annual meeting of stockholders in 2026, and until their successors are duly elected and qualified. The nominees' qualifications are described in this year's proxy statement. Based on the recommendation of the Governance and Nominating Committee, the board has nominated for election the following persons as directors of the company: Richard A. Miller, MD, and Linda S. Grais, MD, JD. The second proposal to be voted on is the ratification of PricewaterhouseCoopers to serve as the independent registered public accounting firm for the company for the fiscal year ending December 31st, 2023. Pricewaterhouse is represented by Mr. Kaba. PricewaterhouseCoopers acted as the company's independent registered public accounting firm for the fiscal year ended December 31st, 2022.

The third proposal to be voted on is a non-binding advisory vote to approve the compensation of our named executive officers. Have any questions come in from the stockholders? No, there are no questions have come in from the stockholders. It is now time to move on to the voting. Please note that we're about to close the polls for voting at this meeting. Please remember that if you've already sent in your proxy or voted by internet or telephone, your shares have been voted accordingly. You do not need to vote today unless you are voting for the first time or want to change your previous vote. We're now gonna take a short pause to allow for any stockholders who have not yet voted to do so. I now declare the polls closed. The proxies and ballots have been counted. Based upon the preliminary vote totals, Richard A.

Miller, MD, and Linda S. Grais, MD, JD, have been elected to the board of directors, and the selection of PricewaterhouseCoopers as the company's independent registered public accounting firm for 2023 has been ratified. Also, on a non-binding advisory basis, the compensation of our named executive officers has been approved. The final vote will be included in the company's current report on Form 8-K to be filed with the Securities and Exchange Commission within 4 business days following this meeting. We have concluded the business part of the annual meeting. We have no other business conducted this meeting. Are there any objections to adjourning the meeting? The meeting is now officially adjourned. Thank you for attending this year's virtual annual meeting. We hope you share our excitement about Corvus and look forward to having you attend next year's annual meeting. Thank you.

Operator

This concludes the meeting. You may now disconnect.

Leiv Lea
CFO, Corvus Pharmaceuticals, Inc

Thank you.

Powered by